The Seiden Group announces U.S. Shareholders formation of a group to recover investor funds through a possible Receivership over China-based Huifeng Bio-Pharmaceutical Technology, Inc (Ticker: HFGB)

NEW YORK, March 21, 2017 /PRNewswire/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (Ticker: HFGB), is a British Virgin Islands corporation involved in the business of manufacturing and marketing pharmaceutical raw materials and ingredients, such as pharmaceuticals used for human and animals, nutraceuticals, cosmetics, functional drink and food. HFGB was de-listed from the NASDAQ in January 2013 after it stopped reporting to the Securities & Exchange Commission ("SEC").

Certain shareholders have spoken with Robert W. Seiden, Esq. in New York to represent a group of shareholders to enforce the rights of the U.S. shareholders for acts detrimental to the investors including failure to report to the SEC in order to get a possible return of capital to the investors.

If you are a current shareholder of HFGB and interested in information to consider joining in the case, please email Nathaniel Francis at the email: nfrancis@csilegal.com or call 212.626.6709 by April 4, 2017. You can also register on the website www.confidentialglobal.com under "Join Receivership Case".